Fly News Breaks for January 9, 2020
Jan 9, 2020 | 05:21 EDT
BMO Capital analyst Do Kim downgraded Constellation Pharmaceuticals (CNST) to Market Perform from Outperform with a price target of $42, down from $43. The analyst believes CPI-0610 clinical success in front-line myelofibrosis is nearly fully priced into shares ahead of Phase 3 start. In comparison to Incyte's (INCY) valuation at the same period of Jakafi development, Constellation trades at a 60% premium, with a market cap closer to Incyte after Phase 3 data, Kim tells investors in a research note. As such, the analyst expect limited upside in Constellation shares from the CPI-0610 Phase 2 MANIFEST updates.
News For CNST;INCY From the Last 2 Days
Feb 16, 2020 | 15:57 EST
Specialty Pharma Analyst Chen, Biotech Analysts Young & Merle, along with Key Opinion Leaders Dr. Goldberg, Skin Laser & Surgery Specialists of NY & NJ and Dr. Weinberg, Forest Hills Dermatology Group, discuss the competitive landscape in atopic dermatitis at a Group Luncheon Meeting being held at Cantor's New York offices on February 24 at 12 pm.